File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in orientals receiving cisplatin chemotherapy: A randomized crossover trial

TitleThe antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in orientals receiving cisplatin chemotherapy: A randomized crossover trial
Authors
Keywordsantiemesis
Chinese
cisplatin
dexamethasone
metoclopramide
tropisetron
Issue Date1996
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCP
Citation
British Journal Of Clinical Pharmacology, 1996, v. 41 n. 5, p. 403-408 How to Cite?
AbstractWe report a single-blind randomized crossover trial comparing the efficacy of tropisetron plus dexamethasone (TROPDEX) vs conventional combination of metoclopramide, dexamethasone and diphenhydramine (METDEX) in prevention of acute and delayed vomiting in Chinese patients receiving high dose cisplatin. Thirty-six consecutive patients with nasopharyngeal carcinoma were entered into the study, all received cisplatin at a dose range of 60-100 mg/m 2. Patients were randomized in the sequence of antiemetic regimens used in two consecutive cycles. The TROPDEX regimen consisting of tropisetron 5 mg i.v. and dexamethasone 20 mg i.v. given on day 1 of chemotherapy, followed by oral maintenance with tropisetron 5 mg daily and dexamethasone 4 mg twice daily from day 2 to 6. The METDEX regimen consisting of metoclopramide 1 mg kg -1 i.v., dexamethasone 20 mg i.v. and diphenhydramine 25 mg i.v. given before chemotherapy and then 2 hourly for two more doses on day 1, followed by oral metoclopramide 20 mg 6 hourly from day 2 to 6. Complete control of acute vomiting was observed in 64% of patients with TROPDEX as compared with 14% with METDEX (P < 0.01). While complete plus major control of acute vomiting was observed in 84% with TROPDEX as compared with 58% with METDEX. The mean vomiting episodes on day 1 were 1.4 with TROPDEX as compared with 3.5 with METDEX (P < 0.01). There was, howewer, no significant difference between the two regimens in the control of delayed vomiting. When patients randomized to TROPDEX in the second cycle were compared with those with TROPDEX in the first cycle, the antiemetic efficacy was reduced, with mean acute vomiting episodes of 2 in the former compared with 0.8 in the latter (P < 0.01). The most common adverse effect observed was headache in TROPDEX (27%) and dizziness in METDEX (40%). In conclusion, the antiemetic regimen TROPDEX is effective in Chinese patients receiving high dose cisplatin chemotherapy and is well tolerated. It is better than conventional METDEX regimen in the control of acute vomiting, but not in the control of delayed vomiting.
Persistent Identifierhttp://hdl.handle.net/10722/48915
ISSN
2015 Impact Factor: 3.83
2015 SCImago Journal Rankings: 1.486
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChua, DTTen_HK
dc.contributor.authorSham, JSTen_HK
dc.contributor.authorAu, GKHen_HK
dc.contributor.authorChoy, Den_HK
dc.contributor.authorKwong, DLWen_HK
dc.contributor.authorYau, CCen_HK
dc.contributor.authorCheng, ACKen_HK
dc.date.accessioned2008-05-30T08:32:59Z-
dc.date.available2008-05-30T08:32:59Z-
dc.date.issued1996en_HK
dc.identifier.citationBritish Journal Of Clinical Pharmacology, 1996, v. 41 n. 5, p. 403-408en_HK
dc.identifier.issn0306-5251en_HK
dc.identifier.urihttp://hdl.handle.net/10722/48915-
dc.description.abstractWe report a single-blind randomized crossover trial comparing the efficacy of tropisetron plus dexamethasone (TROPDEX) vs conventional combination of metoclopramide, dexamethasone and diphenhydramine (METDEX) in prevention of acute and delayed vomiting in Chinese patients receiving high dose cisplatin. Thirty-six consecutive patients with nasopharyngeal carcinoma were entered into the study, all received cisplatin at a dose range of 60-100 mg/m 2. Patients were randomized in the sequence of antiemetic regimens used in two consecutive cycles. The TROPDEX regimen consisting of tropisetron 5 mg i.v. and dexamethasone 20 mg i.v. given on day 1 of chemotherapy, followed by oral maintenance with tropisetron 5 mg daily and dexamethasone 4 mg twice daily from day 2 to 6. The METDEX regimen consisting of metoclopramide 1 mg kg -1 i.v., dexamethasone 20 mg i.v. and diphenhydramine 25 mg i.v. given before chemotherapy and then 2 hourly for two more doses on day 1, followed by oral metoclopramide 20 mg 6 hourly from day 2 to 6. Complete control of acute vomiting was observed in 64% of patients with TROPDEX as compared with 14% with METDEX (P < 0.01). While complete plus major control of acute vomiting was observed in 84% with TROPDEX as compared with 58% with METDEX. The mean vomiting episodes on day 1 were 1.4 with TROPDEX as compared with 3.5 with METDEX (P < 0.01). There was, howewer, no significant difference between the two regimens in the control of delayed vomiting. When patients randomized to TROPDEX in the second cycle were compared with those with TROPDEX in the first cycle, the antiemetic efficacy was reduced, with mean acute vomiting episodes of 2 in the former compared with 0.8 in the latter (P < 0.01). The most common adverse effect observed was headache in TROPDEX (27%) and dizziness in METDEX (40%). In conclusion, the antiemetic regimen TROPDEX is effective in Chinese patients receiving high dose cisplatin chemotherapy and is well tolerated. It is better than conventional METDEX regimen in the control of acute vomiting, but not in the control of delayed vomiting.en_HK
dc.format.extent388 bytes-
dc.format.mimetypetext/html-
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCPen_HK
dc.relation.ispartofBritish Journal of Clinical Pharmacologyen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsBritish Journal of Clinical Pharmacology. Copyright © Blackwell Publishing Ltd.en
dc.rightsThe definitive version is available at www.blackwell-synergy.comen
dc.subjectantiemesisen_HK
dc.subjectChineseen_HK
dc.subjectcisplatinen_HK
dc.subjectdexamethasoneen_HK
dc.subjectmetoclopramideen_HK
dc.subjecttropisetronen_HK
dc.titleThe antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in orientals receiving cisplatin chemotherapy: A randomized crossover trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0306-5251&volume=41&issue=5&spage=403&epage=408&date=1996&atitle=The+antiemetic+efficacy+of+tropisetron+plus+dexamethasone+as+compared+with+conventional+metoclopramide-dexamethasone+combination+in+Orientals+receiving+cisplatin+chemotherapy:+a+randomized+crossover+trialen
dc.identifier.emailChua, DTT: dttchua@hkucc.hku.hken_HK
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_HK
dc.identifier.authorityChua, DTT=rp00415en_HK
dc.identifier.authorityKwong, DLW=rp00414en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1046/j.1365-2125.1996.03268.xen
dc.identifier.pmid8735681-
dc.identifier.pmcidPMC2042600en
dc.identifier.scopuseid_2-s2.0-0029980317en_HK
dc.identifier.hkuros13348-
dc.identifier.volume41en_HK
dc.identifier.issue5en_HK
dc.identifier.spage403en_HK
dc.identifier.epage408en_HK
dc.identifier.isiWOS:A1996UK60700009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChua, DTT=7006773480en_HK
dc.identifier.scopusauthoridSham, JST=7101655565en_HK
dc.identifier.scopusauthoridAu, GKH=7003748615en_HK
dc.identifier.scopusauthoridChoy, D=7102939127en_HK
dc.identifier.scopusauthoridKwong, DLW=15744231600en_HK
dc.identifier.scopusauthoridYau, CC=7007038422en_HK
dc.identifier.scopusauthoridCheng, ACK=36788758900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats